Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

A clinical trial showed that relacorilant, a repurposed drug for Cushing's syndrome, could extend survival in patients with platinum-resistant ovarian cancer. Participants treated with relacorilant lived an average of four months longer than those receiving standard care. Researchers propose relacorilant as a potential new standard treatment for this aggressive cancer.

Read full article on The Guardian Australia →

Summary by Glance · Original reporting by The Guardian Australia